3-bromometkatinonas

3-Bromomethcathinone (3-BMC) is a stimulant designer drug and monoamine releasing agent of the cathinone family. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), with EC50Tooltip half-maximal effective concentration values for induction of monoamine release of 136–137 nM for serotonin, 25 nM for norepinephrine, and 21–28 nM for dopamine in rat brain synaptosomes. The drug produces hyperlocomotion in rodents comparably to but with slightly lower potency than methcathinone. The chemical synthesis of 3-BMC has been described. 3-BMC was first described in the scientific literature by 2002. It emerged as a novel designer drug in Israel and Germany and elsewhere in 2009.

Also known as: 1-(3-bromophenyl)-2-(methylamino)propan-1-one, 3-BMC

Classification

Chemical: Cathinone
Psychoactive: Stimulant

Effects

Increased Heart Rate
Stimulation
Talkativeness
Alertness Enhancement
Light Sensitivity

Routes of Administration

No route information available yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

wikipedia.org

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu